New Mexico Educational Retirement Board Has $1.93 Million Holdings in Exelixis, Inc. (NASDAQ:EXEL)

New Mexico Educational Retirement Board decreased its holdings in Exelixis, Inc. (NASDAQ:EXEL - Free Report) by 12.6% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 57,855 shares of the biotechnology company's stock after selling 8,345 shares during the quarter. New Mexico Educational Retirement Board's holdings in Exelixis were worth $1,927,000 as of its most recent filing with the SEC.

Other large investors also recently modified their holdings of the company. MassMutual Private Wealth & Trust FSB increased its stake in shares of Exelixis by 18.1% during the fourth quarter. MassMutual Private Wealth & Trust FSB now owns 1,890 shares of the biotechnology company's stock valued at $63,000 after acquiring an additional 290 shares during the period. Covestor Ltd boosted its stake in Exelixis by 5.7% during the 3rd quarter. Covestor Ltd now owns 6,335 shares of the biotechnology company's stock valued at $164,000 after purchasing an additional 341 shares in the last quarter. V Square Quantitative Management LLC increased its position in shares of Exelixis by 37.3% during the 4th quarter. V Square Quantitative Management LLC now owns 1,563 shares of the biotechnology company's stock valued at $52,000 after purchasing an additional 425 shares during the period. Fifth Third Bancorp raised its stake in shares of Exelixis by 16.1% in the 4th quarter. Fifth Third Bancorp now owns 3,231 shares of the biotechnology company's stock worth $108,000 after buying an additional 449 shares in the last quarter. Finally, UMB Bank n.a. lifted its holdings in shares of Exelixis by 68.4% in the fourth quarter. UMB Bank n.a. now owns 1,361 shares of the biotechnology company's stock valued at $45,000 after buying an additional 553 shares during the period. 85.27% of the stock is owned by institutional investors and hedge funds.

Exelixis Stock Up 0.1 %

EXEL stock traded up $0.02 during trading hours on Thursday, hitting $35.09. The company's stock had a trading volume of 1,782,075 shares, compared to its average volume of 2,601,005. The stock has a 50 day moving average price of $34.16 and a two-hundred day moving average price of $31.11. Exelixis, Inc. has a 12 month low of $20.14 and a 12 month high of $37.59. The company has a market capitalization of $9.82 billion, a PE ratio of 19.82, a price-to-earnings-growth ratio of 1.10 and a beta of 0.53.

Exelixis (NASDAQ:EXEL - Get Free Report) last posted its earnings results on Tuesday, February 11th. The biotechnology company reported $0.48 EPS for the quarter, missing the consensus estimate of $0.51 by ($0.03). Exelixis had a return on equity of 23.52% and a net margin of 24.04%. Sell-side analysts expect that Exelixis, Inc. will post 2.04 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on the company. Guggenheim reaffirmed a "buy" rating and set a $42.00 target price on shares of Exelixis in a report on Wednesday, February 12th. StockNews.com raised shares of Exelixis from a "buy" rating to a "strong-buy" rating in a research note on Wednesday. Royal Bank of Canada reissued an "outperform" rating and set a $34.00 target price on shares of Exelixis in a research note on Wednesday, October 30th. JMP Securities reaffirmed a "market outperform" rating and issued a $41.00 price target on shares of Exelixis in a report on Thursday, January 23rd. Finally, Stifel Nicolaus upped their price target on Exelixis from $30.00 to $36.00 and gave the company a "hold" rating in a report on Wednesday, February 12th. One analyst has rated the stock with a sell rating, seven have given a hold rating, twelve have given a buy rating and one has assigned a strong buy rating to the stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $37.24.

Insider Activity

In related news, Director Mary C. Beckerle sold 12,210 shares of the company's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $34.88, for a total transaction of $425,884.80. Following the completion of the sale, the director now directly owns 30,406 shares of the company's stock, valued at approximately $1,060,561.28. This represents a 28.65 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Jeffrey Hessekiel sold 60,000 shares of Exelixis stock in a transaction on Friday, November 29th. The stock was sold at an average price of $36.67, for a total transaction of $2,200,200.00. Following the completion of the transaction, the executive vice president now owns 486,059 shares in the company, valued at $17,823,783.53. This trade represents a 10.99 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders have sold 82,210 shares of company stock valued at $2,978,785. Insiders own 2.85% of the company's stock.

Exelixis Profile

Exelixis, Inc, an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer.